Ventus Therapeutics

Ventus is a biopharmaceutical company utilizing structural biology and computational tools to identify and develop small molecule therapeutics across a broad range of disease indications.

Ventus is focused on discovering and developing novel therapeutics that target the innate immune system with the goal of addressing autoimmune diseases, inflammatory diseases, and cancer.

Ventus was founded in 2019 by Hao Wu, Richard Flavell, Judy Lieberman, Thomas Tuschl, and Feng Shao. The company is headquartered in Montreal, Quebec,  with an office in Natick, MA.


Ventus has developed a proprietary drug discovery platform, called ReSOLVE, which is built upon their structural biology and protein science expertise and their proprietary computational chemistry capabilities, to address the current limitations of small molecule drug discovery.


Ventus leverages its ReSOLVE platform to discover and characterize previously unknown or poorly understood pockets on the surface of proteins, and identify small molecules that can bind to those pockets with optimal affinity.


Ventus’ lead drug program, VENT-01, is a peripherally restricted small molecule inhibitor compound targeting NLRP3. NLRP3 is a key mediator of pro-inflammatory cytokines IL-1b and IL-18 and is a biologically validated target for many diseases where inflammation is the key driver of pathology.


Ventus is backed by SoftBank Vision Fund 2, RA Capital Management, Qatar Investment Authority, Andreessen Horowitz, Versant Ventures, GV, BVF Partners, Casdin Capital, Cormorant Asset Management, and others. The company raised $140M in Series C round on Feb 09, 2022. This brings Ventus' total funding to $300M to date.



  • Year founded: 2019
  • Funding Info: $300M over 3 Rounds (Latest Funding Type: Series C)
  • Yearly Revenue: NA
  • Employee Size: 51-200
  • Business Valuation: NA
  • City/Town: Montreal
  • State: Quebec
  • Country: Canada
Related businesses